• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Anthony G. Letai, MD, PHD


  • Hata AN, Yeo A, Faber AC, Lifshits E, Chen Z, Cheng KA, Walton Z, Sarosiek KA, Letai A, Heist RS, Mino-Kenudson M, Wong KK, Engelman JA.Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS-mutant lung cancers.Cancer Res. 2014 Jun 1(11):3146-56.
  • Pan R, Hogdal LJ, Benito JM, Bucci D, Han L, Borthakur G, Cortes J, DeAngelo DJ, Debose L, Mu H, Döhner H, Gaidzik VI, Galinsky I, Golfman LS, Haferlach T, Harutyunyan KG, Hu J, Leverson JD, Marcucci G, Müschen M, Newman R, Park E, Ruvolo PP, Ruvolo V, Ryan J, Schindela S, Zweidler-McKay P, Stone RM, Kantarjian H, Andreeff M, Konopleva M, Letai AG.Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia.Cancer Discovery. 2014 Mar;4(3):362-75.
  • Liu JC, Guan X, Ryan JA, Rivera AG, Mock C, Agrawal V, Agarwal V, Letai A, Lerou PH, Lahav G.High mitochondrial priming sensitizes hESCs to DNA-damage-induced apoptosis.Cell Stem Cell. 2013 Oct 3;13(4):483-91.
  • Davids MS, Letai A, Brown JR.Overcoming stroma-mediated treatment resistance in chronic lymphocytic leukemia through BCL-2 inhibition.Leuk Lymphoma. 2013 Apr 25.
  • Ryan J, Letai A.BH3 Profiling in Whole Cells by Flourimeter or FACS.Methods. 2013 Apr 19.
  • Etchin J, Sanda T, Mansour MR, Kentsis A, Montero J, Le BT, Christie AL, McCauley D, Rodig SJ, Kauffman M, Shacham S, Stone R, Letai A, Kung AL, Thomas Look A.KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia.British Journal of Haematology. 2013 Apr;161(1):117-27.
  • Hogdal LJ, Letai A.BCL-2 inhibition: stemming the tide of myeloid malignancies.Cell Stem Cell. 2013 Mar 7;12(3):269-70.
  • Davids MS, Letai A.ABT-199: taking dead aim at BCL-2.Cancer Cell. 2013 Feb 11;23(2):139-41.
  • Davids MS, Deng J, Wiestner A, Lannutti BJ, Wang L, Wu CJ, Wilson WH, Brown JR, Letai A.Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia.Blood. 2012 Oct 25;120(17):3501-9.
  • Ercan D, Xu C, Yanagita M, Monast CS, Pratilas CA, Montero J, Butaney M, Shimamura T, Sholl L, Ivanova EV, Tadi M, Rogers A, Repellin C, Capelletti M, Maertens O, Goetz EM, Letai A, Garraway LA, Lazzara MJ, Rosen N, Gray NS, Wong KK, Jänne PA.Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.Cancer Discovery. 2012 Oct;2(10):934-47.
  • Vo TT, Ryan J, Carrasco R, Neuberg D, Rossi DJ, Stone RM, Deangelo DJ, Frattini MG, Letai A.Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML.Cell. 2012 Oct 12;151(2):344-55.
  • Dutta C, Day T, Kopp N, van Bodegom D, Davids MS, Ryan J, Bird L, Kommajosyula N, Weigert O, Yoda A, Fung H, Brown JR, Shapiro GI, Letai A, Weinstock DM.BCL2 suppresses PARP1 function and nonapoptotic cell death.Cancer Res. 2012 Aug 15;72(16):4193-203.
  • Letai A.A new face of BCL-2 inhibition in CLL.Blood. 2011 Mar 10;117(10):2750-1.
  • Vo TT, Letai A.BH3-only proteins and their effects on cancer.Adv Exp Med Biol. 2010;687:49-63. Review.
  • Ryan JA, Brunelle JK, Letai A.Heightened mitochondrial priming is the basis for apoptotic hypersensitivity of CD4+ CD8+ thymocytes.Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):12895-900.
  • Yecies D, Carlson NE, Deng J, Letai A.Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1.Blood. 2010 Apr 22;115(16):3304-13.
  • Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, Mc Henry KT, Pinchback RM, Ligon AH, Cho YJ, Haery L, Greulich H, Reich M, Winckler W, Lawrence MS, Weir BA, Tanaka KE, Chiang DY, Bass AJ, Loo A, Hoffman C, Prensner J, Liefeld T, Gao Q, Yecies D, Signoretti S, Maher E, Kaye FJ, Sasaki H, Tepper JE, Fletcher JA, Tabernero J, Baselga J, Tsao MS, Demichelis F, Rubin MA, Janne PA, Daly MJ, Nucera C, Levine RL, Ebert BL, Gabriel S, Rustgi AK, Antonescu CR, Ladanyi M, Letai A, Garraway LA, Loda M, Beer DG, True LD, Okamoto A, Pomeroy SL, Singer S, Golub TR, Lander ES, Getz G, Sellers WR, Meyerson M.The landscape of somatic copy-number alteration across human cancers.Nature. 2010 Feb 18;463(7283):899-905.
  • Brunelle JK, Ryan J, Yecies D, Opferman JT, Letai A.MCL-1-dependent leukemia cells are more sensitive to chemotherapy than BCL-2-dependent counterparts.J Cell Biol. 2009 Nov 2;187(3):429-42.
  • Dutta-Simmons J, Zhang Y, Gorgun G, Gatt M, Mani M, Hideshima T, Takada K, Carlson NE, Carrasco DE, Tai YT, Raje N, Letai AG, Anderson KC, Carrasco DR.Aurora kinase A is a target of Wnt/beta-catenin involved in multiple myeloma disease progression.Blood. 2009 Sep 24;114(13):2699-708.
  • Letai A.Hiding from ABT-737 in lymph nodes.Blood. 2009 Apr 30;113(18):4132-3.
  • Letai A.Puma strikes Bax.J Cell Biol. 2009 Apr 20;185(2):189-91.
  • Brunelle JK, Letai A.Control of mitochondrial apoptosis by the Bcl-2 family.J Cell Sci. 2009 Feb 15;122(Pt 4):437-41. Review.
  • Jette CA, Flanagan AM, Ryan J, Pyati UJ, Carbonneau S, Stewart RA, Langenau DM, Look AT, Letai A.BIM and other BCL-2 family proteins exhibit cross-species conservation of function between zebrafish and mammals.Cell Death Differ. 2008 Jun;15(6):1063-72.
  • Del Gaizo Moore V, Letai A.Rational design of therapeutics targeting the BCL-2 family: are some cancer cells primed for death but waiting for a final push?.Adv Exp Med Biol. 2008;615:159-75. Review.
  • Kutuk O, Letai A.Regulation of Bcl-2 family proteins by posttranslational modifications.Curr Mol Med. 2008 Mar;8(2):102-18. Review.
  • Letai AG.Diagnosing and exploiting cancer's addiction to blocks in apoptosis.Nat Rev Cancer. 2008 Feb;8(2):121-32. Review.
  • Deng J, Shimamura T, Perera S, Carlson NE, Cai D, Shapiro GI, Wong KK, Letai A.Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion.Cancer Res. 2007 Dec 15;67(24):11867-75.
  • Flanagan AM, Letai A.BH3 domains define selective inhibitory interactions with BHRF-1 and KSHV BCL-2.Cell Death Differ. 2008 Mar;15(3):580-8.
  • Del Gaizo Moore V, Schlis KD, Sallan SE, Armstrong SA, Letai A.BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia.Blood. 2008 Feb 15;111(4):2300-9.
  • Deng J, Carlson N, Takeyama K, Dal Cin P, Shipp M, Letai A.BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents.Cancer Cell. 2007 Aug;12(2):171-85.
  • Del Gaizo Moore V, Brown JR, Certo M, Love TM, Novina CD, Letai A.Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737.J Clin Invest. 2007 Jan;117(1):112-21.
  • Letai A.Restoring cancer's death sentence.Cancer Cell. 2006 Nov;10(5):343-5.
  • Goldsmith KC, Liu X, Dam V, Morgan BT, Shabbout M, Cnaan A, Letai A, Korsmeyer SJ, Hogarty MD.BH3 peptidomimetics potently activate apoptosis and demonstrate single agent efficacy in neuroblastoma.Oncogene. 2006 Aug 3;25(33):4525-33.
  • Letai A, Scorrano L.Laying the foundations of programmed cell death.Cell Death Differ. 2006 Aug;13(8):1245-7.
  • Certo M, Del Gaizo Moore V, Nishino M, Wei G, Korsmeyer S, Armstrong SA, Letai A.Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members.Cancer Cell. 2006 May;9(5):351-65.
  • Letai A.Growth factor withdrawal and apoptosis: the middle game.Mol Cell. 2006 Mar 17;21(6):728-30. Review.
  • Chauhan D, Catley L, Li G, Podar K, Hideshima T, Velankar M, Mitsiades C, Mitsiades N, Yasui H, Letai A, Ovaa H, Berkers C, Nicholson B, Chao TH, Neuteboom ST, Richardson P, Palladino MA, Anderson KC.A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib.Cancer Cell. 2005 Nov;8(5):407-19.
  • Letai A.Pharmacological manipulation of Bcl-2 family members to control cell death.J Clin Invest. 2005 Oct;115(10):2648-55.
  • Letai A.BCL-2: found bound and drugged!.Trends Mol Med. 2005 Oct;11(10):442-4.
  • Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, Joseph MK, Kitada S, Korsmeyer SJ, Kunzer AR, Letai A, Li C, Mitten MJ, Nettesheim DG, Ng S, Nimmer PM, O'Connor JM, Oleksijew A, Petros AM, Reed JC, Shen W, Tahir SK, Thompson CB, Tomaselli KJ, Wang B, Wendt MD, Zhang H, Fesik SW, Rosenberg SH.An inhibitor of Bcl-2 family proteins induces regression of solid tumours.Nature. 2005 Jun 2;435(7042):677-81.
  • Letai A, Sorcinelli MD, Beard C, Korsmeyer SJ.Antiapoptotic BCL-2 is required for maintenance of a model leukemia.Cancer Cell. 2004 Sep;6(3):241-9.
  • Opferman JT, Letai A, Beard C, Sorcinelli MD, Ong CC, Korsmeyer SJ.Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1.Nature. 2003 Dec 11;426(6967):671-6.
  • Letai A.BH3 domains as BCL-2 inhibitors: prototype cancer therapeutics.Expert Opin Biol Ther. 2003 Apr;3(2):293-304.
  • Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, Korsmeyer SJ.Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics.Cancer Cell. 2002 Sep;2(3):183-92.